At closing price yielding 6.4% with probable final div increasing as well. Although good to have major clients the Astra zeneca loss may not be so bad if replaced by a few smaller customers.
- Forums
- ASX - By Stock
- CKL
- Ann: Half Yearly Report
Ann: Half Yearly Report , page-3
Featured News
Add CKL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online